• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    375.50 +0.21 (+0.06%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 111,098
    Open 374.36
    Bid (Size) 375.12 (4)
    Ask (Size) 375.50 (7)
    Prev. Close 375.29
    Today's Range 371.75 - 377.06
    52wk Range 327.73 - 550.76
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Analyst Verdict: argenx In The Eyes Of 12 Experts
    Via Benzinga
    argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
    From argenx SE
    Via GlobeNewswire

    Performance

    YTD
    -1.44%
    -1.44%
    1 Month
    -5.49%
    -5.49%
    3 Month
    -2.37%
    -2.37%
    6 Month
    -19.10%
    -19.10%
    1 Year
    -4.27%
    -4.27%

    More News

    Read More
    Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
    Via Benzinga
    argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
    From argenx SE
    Via GlobeNewswire
    argenx Announces Annual General Meeting of Shareholders on May 7, 2024
    From argenx SE
    Via GlobeNewswire
    Key Takeaways From argenx Analyst Ratings
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
    From argenx SE
    Via GlobeNewswire
    Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
    Via Benzinga
    Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
    From argenx SE
    Via GlobeNewswire
    argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
    From argenx SE
    Via GlobeNewswire
    3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
    Via InvestorPlace
    argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    5 medical stocks growing earnings by triple digits
    Via MarketBeat
    Topics Economy
    Exposures Economy
    New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
    Via Benzinga
    Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
    Via Benzinga
    argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
    From argenx SE
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.